CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma
CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma
复制标题
DOI：
10.1002/cyto.b.21384
复制
发表时间：
2018-01-01
影响因子：
3.4
通讯作者：
Roth, Christine G.
中科院分区：
文献类型：
--
作者：
Gooden, Casey E.;Jones, Patricia;Roth, Christine G.
背景CD 49 d是慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）的一个强有力的不良预后标志物。然而，流式细胞术检测CD 49 d在美国尚未被广泛采用，部分原因是缺乏其在临床环境中的性能特征的建立，特别是与更常见的CLL/SLL预后标志物CD 38和ZAP-70的比较。方法对124例CLL/SLL患者的外周血（PB）、骨髓（BM）、和淋巴结（LN）标本，并与可用的CD 38和ZAP-70表达和细胞遗传学结果。对于10个PB/BM标本，在24小时内评估CD 49 d、CD 38和ZAP-70表达的稳定性。
BackgroundCD49d is emerging as a powerful adverse prognostic marker in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). However, flow cytometric testing for CD49d has not yet been widely adopted in the United States, in part due to the lack of establishment of its performance characteristics in the clinical setting, especially in comparison with the more common CLL/SLL prognostic markers CD38 and ZAP-70.MethodsCD49d expression levels in 124 CLL/SLL cases were assessed among peripheral blood (PB), bone marrow (BM), and lymph node (LN) specimens and correlated with available CD38 and ZAP-70 expression and cytogenetic findings. For 10 PB/BM specimens, the stability of CD49d, CD38, and ZAP-70 expression was assessed at